World Workshop on Oral Medicine VI: clinical implications of medication-induced salivary gland dysfunction

TY - JOUR

T1 - World Workshop on Oral Medicine VI

T2 - clinical implications of medication-induced salivary gland dysfunction

AU - Aliko, Ardita

AU - Wolff, Andy

AU - Dawes, Colin

AU - Aframian, Doron

AU - Proctor, Gordon

AU - Ekström, Jörgen

AU - Narayana, Nagamani

AU - Villa, Alessandro

AU - Sia, Ying Wai

AU - Joshi, Revan Kumar

AU - McGowan, Richard

AU - Beier Jensen, Siri

AU - Kerr, A Ross

AU - Pedersen, Anne Marie Lynge

AU - Vissink, Arjan

N1 - Copyright © 2015 Elsevier Inc. All rights reserved.

PY - 2015/8

Y1 - 2015/8

N2 - OBJECTIVE: This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD).STUDY DESIGN: The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size.RESULTS: For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations.CONCLUSIONS: The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.

AB - OBJECTIVE: This study aimed to systematically review the available literature on the clinical implications of medication-induced salivary gland dysfunction (MISGD).STUDY DESIGN: The systematic review was performed using PubMed, Embase, and Web of Science (through June 2013). Studies were assessed for degree of relevance and strength of evidence, based on whether clinical implications of MISGD were the primary study outcomes, as well as on the appropriateness of study design and sample size.RESULTS: For most purported xerogenic medications, xerostomia was the most frequent adverse effect. In the majority of the 129 reviewed papers, it was not documented whether xerostomia was accompanied by decreased salivary flow. Incidence and prevalence of medication-induced xerostomia varied widely and was often associated with number and dose of medications. Xerostomia was most frequently reported to be mild-to-moderate in severity. Its onset occurred usually in the first weeks of treatment. There was selected evidence that medication-induced xerostomia occurs more frequently in women and older adults and that MISGD may be associated with other clinical implications, such as caries or oral mucosal alterations.CONCLUSIONS: The systematic review showed that MISGD constitutes a significant burden in many patients and may be associated with important negative implications for oral health.

U2 - 10.1016/j.oooo.2014.10.027

DO - 10.1016/j.oooo.2014.10.027

M3 - Journal article

C2 - 25861957

SN - 1079-2104

VL - 120

SP - 185

EP - 206

JO - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

JF - Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology

IS - 2

ER -